Two-Drug combo aims to outsmart advanced lung cancer

NCT ID NCT06616623

Recruiting now Disease control Sponsor: Dwight Owen Source: ClinicalTrials.gov ↗

First seen Jan 06, 2026 · Last updated May 01, 2026 · Updated 16 times

Summary

This early-stage trial is testing whether combining vismodegib (a drug that blocks cancer cell growth) with atezolizumab (an immunotherapy that helps the immune system attack cancer) is safe and tolerable for people with advanced non-small cell lung cancer that has returned or spread. About 24 adults who have already tried standard treatments will receive both drugs. The main goal is to find the best dose and understand side effects, while also checking if the combination helps control the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

METASTATIC LUNG NON-SMALL CELL CARCINOMA RECURRENT LUNG NON-SMALL CELL CARCINOMA STAGE IV LUNG CANCER AJCC V8 STAGE IV LUNG CANCER AJCC V8